OASIS

There are a limited number of antibacterial agents active against multidrug-resistant (MDR) and extensively drug-resistant Gram-negative priority pathogens, as defined by The World Health Organization.¹ Imipenem-relebactam is a novel carbapenem-β-lactamase inhibitor combination recommended as a front-line treatment option for MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales (CRE). The available clinical evidence for imipenem-relebactam is limited to two phase-III randomized clinical trials that enrolled few patients infected with these pathogens.^2,3 Real-world evidence is emerging, but limited by significant heterogeneity, residual confounding, and the lack of a comparison between the effectiveness of imipenem-relebactam versus comparator agents.